Tumor Board Tuesday 2023: Genitourinary Cancers


Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.


Supported by educational grants from Astellas; Astrazeneca Pharmaceuticals; Exelixis; Gilead Sciences, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck Sharp & Dohme Corp; and Seagen.


Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

Johnathan Ebben, MD, PhD
Oncology Fellow
Division of Hematology, Oncology, and Palliative Care
University of Wisconsin-Madison
Madison, Wisconsin


#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time. You can join the conversation at https://twitter.com/TumorBoardTues

Tuesday, November 28, 2023cardio tox in Prostate Cancer
AMA credit
Kevin C. Soares, MD, MS
Assistant Attending Surgeon, Hepatopancreatobiliary Service
Memorial Sloan-Kettering Cancer Center
Member, David Rubenstein Center for Pancreatic Cancer Research
Assistant Professor of Surgery, Cornell University, Weill Medical College

Matthew McMillan, MD
Resident Physician
Department of Radiation Oncology
Memorial Sloan-Kettering Cancer Center
Kevin C. Soares, MD, MS has no real or apparent conflicts to disclose.

Matthew McMillan, MD has no real or apparent conflicts to disclose.
Tuesday, October 31, 2023PARPi combo in mCRPC
AMA credit
Neeraj Agarwal, MD, FASCO
Senior Director for Clinical Translation
Directior, Genitourinary Oncology Program
Huntsman Cancer Institute
University of Utah (NCI-CCC)

Vinay Thomas, MD
Clinical Fellow
Huntsman Cancer Institute
University of Utah (NCI-CCC)
Neeraj Agarwal, MD, FASCO has no real or apparent conflicts to disclose.

Vinay Thomas, MD has no real or apparent conflicts to disclose.
Tuesday, October 17, 2023RCC - Progressive Disease - ipilimumab-nivolumab progressor
AMA credit
Amanda Nizam, MD
Associate Staff, Genitourinary Medical Oncology
Cleveland Clinic Taussig Cancer Institute

Yu-Wei Chen, MD, MS
Assistant Clinical Professor of Medicine
University of California San Diego
Amanda Nizam, MD
Consultant: AVEO Oncology, an LG Chem Company

Yu-Wei Chen, MD
Consultant: Janssen Scientific Affairs
Tuesday, September 19, 2023PARPi combo in mCRPC
AMA credit
Shilpa Gupta, MD
Director, Genitourinary Oncology
Hematology and Oncology Department
Cleveland Clinic Taussig Cancer Institute

Albert Jang, MD
Hematology and Oncology Fellow
University Hospitals Seidman Cancer Center
Case Western Reserve University
Case Comprehensive Cancer Center
Shilpa Gupta, MD has no real or apparent conflicts to disclose.

Albert Jang, MD has no real or apparent conflicts to disclose.
Tuesday, August 15, 2023Perioperative mUC
AMA credit
Matthew D. Galsky, MD
Professor of Medicine
Department of Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Jonathan Anker, MD, PhD
Clinical and Research Fellow
Department of Hematology and Medical Oncology
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Matthew D. Galsky, MD
Advisory Board: Abbvie, Alligator, Analog Devices, Asieris, Astra Zeneca, Basilea, Bicycle, Bristol Myers Squibb, Curis, Dragonfly, EMD Serono, Fujifilm, Genentech, Gilead, GlaxoSmithKline, Janssen, Merck, Numab, Pfizer, Rappta Therapeutics, SeaGen, Silverback, UroGen, Veracyte
Research: Astra Zeneca, Bristol Myers Squibb, Dendreon, Genentech, Merck, Novartis

Jonathan Anker, MD, PhD has no real or apparent conflicts to disclose
Tuesday, July 18, 2023
IO Refractory Pt w/RCC
AMA credit
Brian Rini, MD
Chief of Clinical Trials
Department of Hematology/Oncology Vanderbilt University Medical Center Nashville, Tennessee

Katy Beckermann, MD, PhD
Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Brian Rini, MD
Consultant: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Merck, Corvus, Surface Oncology, Aravive, Alkermes, Arrowhead, Eisai, Nikang Therapeutics, EUSA, Athenex, Debiopharm, HiberCell
Funding to Institution for Research: AVEO, Arcus, Merck, Dragonfly Therapeutics, HiberCell, Incyte, Stata Oncology, ADC Therapeutics, Dracen Pharmaceuticals, Janssen, Adela, Astra-Zeneca, Pionyr, Tempus, VasGene Therapeutics, Gilead, POINT Biopharma, BMS, Pfizer, Daiichi Sankyo, Genentech, Arrowhead Pharmaceuticals, Exelixis, Surface Oncology, Aravive

Katy Beckermann, MD, PhD
Consultant: Alpine Bioscience, Aravive, Astrazeneca, Exelixis, Merck, Seagen, Sanofi, BMS
Tuesday, May 9, 2023Cisplatin-ineligible mUC Tx
AMA credit
Petros Grivas, MD, PhD
Professor, Department of Medicine, Division of Medical Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Fred Hutchinson Cancer Center
Seattle, Washington

Rafee Talukder, MD
University of Washington
Fred Hutch Cancer Center
Seattle, Washington
Petros Grivas, MD, PhD
Consulting: 4D Pharma, Aadi Bioscience, Asieris Pharmaceuticals, Astellas Pharma, AstraZeneca, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis, Fresenius Kabi, G1 Therapeutics, Genentech, Gilead Sciences, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Lucence, Mirati Therapeutics, MSD, Pfizer, PureTech, Regeneron, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, QED Therapeutics, Merck KGaA, UroGen Pharma
Institutional Research Funding: Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Mirati Therapeutics, MSD, Pfizer, QED Therapeutics, Merck KGaA

Rafee Talukder, MD has no real or apparent conflicts to disclose

Stay tuned for upcoming conversations!


Oncologists and other clinicians who treat patients with genitourinary (GU) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of renal cell carcinoma, prostate, bladder and other GU related cancers. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GU cancers that benefit patients is instrumental in improving patient outcomes. Oncologists and urologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.


This activity is designed to meet the needs of medical, surgical and radiation oncologists, urologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in the treatment and management of patients with genitourinary cancer.


Upon completion of this educational activity, participants will be able to:


There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

If you wish to claim credit for your participation in TBT conversations from March 21, 2023 – Present you can do so here: www.integrityce.com/TBTeval23




Physician Continuing Education

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this live material for a maximum of 7.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

Johnathan Ebben, MD, PhD
Other (CEO): NanoRED

The Integrity Continuing Education, Inc. planners and managers and Tumor Board Tuesday patient planner do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.